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WHICH LIVER-DISEASE 
PATIENTS NEED 
A TRANSPLANT? 
Organ replacement has come into its own as a treatment for 
end-stage liver disease. A team of experts from two leading 
transplant centers reviews curren1 indications. survival rates. 
and methods of evaluating candidates for operation. 
By Leonard Makowka. MD, PhD. Linda Sher, MD, Delawir Kahn, 
MD. Thomas E. Starz!. MD. PhD. et 01-
lIver transplantatIOn is now the 
&I treatment of choice for many 
patIents with end·stage liver dis· 
ease I .] Since the introductIOn of 
the Immun05uppreSSI\'e agent cy-
clospoTine in 1978. 4 organ re-
placement has gained acceptance 
as thr only int.en-entlon that can 
cure thl~ relentless. chromc pro· 
ce!'!' and offer thE' chance of com-
plett' rehabilitatIon 
One·yt-ar sun'j\'al rates of 70(( 
or bett~r haH' been reported for 
many grE-Irm~ of patients Sf' The 
ma.l(orI!\ can look forward to long. 
productJ\'t- liyDe~ The opHatlOn 
now car. be recommended to per-
som formerly thought to be at 
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prohIbitively hIgh Tlsk because of 
their particular disease. prior ab-
dominal surgery. extreme youth. 
or advancPd age. The youngest 
and oldest recipients of successful 
transplants at our institutions 
were 3 1'2 weeks and i6 years old. 
Refinements in surgical tech-
nique have contnbuted to these 
improvPd results, particularly the 
introduction of the venovenous 
b~"mas;:K~ improHments In biliary 
tract reconst ruction. ~ and the de-
velopment of methods fOT mUltiple 
orpm procurement ~·l J For a de-
scnptlOn of how the uperatlom on 
donor and reCIpient are done. see 
"Current surgIcal tE'chnlquf:." 
page 78. 
P Al1l:NT EVALUATION 
Even though most patients are reo 
ferred to a transplant center WIth 
an established diagnOSIs. each 
person IS thoroughl~D evaluated to 
assess suitability and fitness for 
operatIon. We take a careful his-
tory. pa~Ding special atte-ntior. te 
alcohol and drug abuse. blood· 
product transfusions. conCOmJ:3nt 
illnesses. pre\'iou5 operatlcns. 
medIcatIOn::. and exposure to u:>x-
ins. During the phY81cal exam::;a· 
tion. we look for xanthomas and 
Kayser-Fleischer rings. whIch are 
associated With primar~D blliar\' 
cirrhosis and Wilson's diHase. 
respectively. 
MeTltal status i::: assessed We 
grade encephalopath~·K accor:mg 
t() its severity ITable 1'. and t!'y to 
identify preclpitaunll cat:~esK 
!'uch as deh~·dratgonK mf£-ctJCIT .. or 
gastrointestinal ,GI, ble£-cirI~ 
More se\'ere ('ases are mana~td Ir. 
the inti-nSIH care unit: endC'tra· 
cheal intubatIon IS sometlme:' 
necessar~D to pren·nt aSplro!l(,n 
Patients ..... ith enc€'ph3Iopatr.\' an; 
gi\'en neom~Dcin and laC'tulo::1:' 
RoutIne hlooa ttD!Dt~ indudt-
CBC. full coagulation profdt-. 11\· 
e-r-function tests. mea::ures of ::f" 
rum electrolyt~s and glucost'. and 
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lJV!R TRANSPLANT AnON 
nGURE 1. When a transplant candida1e's portal TeUl 
cannot be T1sualUed on ultrasound or Doppler 
ezammation, angiography is penormed. At lett, the 
Tenous phase of a splenic arteriogram demonstra1es 
confluence of the 1n1erior mesenteric TeUl and the 
splenic Te1n witb absence of tbe portal nUl (anow). 
At rigbt. tbe Tenous pbase of a superior mesenteric 
arteriogram in tbe same patient demonstra1es 
absence 01 the superior mesenteric Tein (anow). 
Such abnormalities can otten be repailed by 
throm.bectomy, anastomosis, or a graft a1 the t1me of 
operation. 
renal-function tests. Abnormali· 
ties in the coagulation profile 
should be corrected before any in· 
vaslve procedures are done. Re-
nal·function abnormalities are in-
vestIgated. in order to distinguIsh 
among the hepatorenal syndrome. 
simpl!:' dehydration ldue to chron-
ic dIUretic therapy and ascites '. 
and mtrinsic renal disease. Mor· 
bldlty and mortality are mcreased 
In patient!: who develop renal fall· 
ure during the posttransplant ~­
nod. matlen~ who have end-stagt.-
liver dlSE'aSe and irreversIblE' re-
nal failure can be managed sue· 
cessfullY with combined liver-kId· 
ney tra~splantatllnKl:t 
We have found the indocyanine 
clearance study' useful in assess-
ing residual liver function and in 
64 alApklp!~ June J 988 
determining the urgency of a pa-
tient's need for a transplant. After 
an initIal loading dose of 0.5 
mg 'kg, indocyanme retention is 
measured at five-minute inter-
vals. A retention of 51':( or greater 
at 20 minutes constitutes e\'i-
dence of liHr diseaSE-: values 
great~r than 301':( or SOC-; indIcate 
SIgnificant or very SE-"'ere lI\'er 
disease. resp€'ctin·ly 
Upper·GI endoscopy is per-
formed to detect esophageal van· 
ces. Persons who havE' a history of 
variceal bleeding or ha\'e severe 
varices at endoscopy are treated 
with injPctlOn sclerotherapy. Co· 
lonoscopy may hE- performed to dE:" 
tect other patholopc conditiom:. 
such as inflammatory bowel dIS' 
ease (lBD! or neopla~ia in pa-
tients WIth pnmary sclerosin~ 
cholangi tis. 
Ultrasound and Doppler studlE'!' 
determine the patency of the por-
tal vein. hepatic artery. hepatIC' 
veins. and vena cava. AngIOgra-
phy is reserved for patIents whosf 
portal veln~ cannot bE' ,-isuahzec 
by noninvaSIve meam and for 
thOSE- with pre\"l(,US portosY5'teml( 
yDenou~ shunts: It is important t( 
assess the status of both the shun~ 
and th!:' portal vem. 
A thrombosed portal vein (FIg, 
urc 11. once an absolute contram· 
dication to ll\'er transplantatlor. 
i~ now only a relative contraindl' 
catIon. It IS often po~sible either tr 
perform a thrombectom~D on th,= 
reCIpient portal vem. to anastL'-
mose the donor porta) vE-in. or tc 
.s.. .., J _ 
k .. .,..:. 'Ofrlt.,·,c.,,-.. . . 
interpose a graft of donor iliac 
'.em at the confluence of the recip-
ient mesenteric and splenic 
vems. IJ 
The transplant center's social 
sernce department evaluates all 
candidates Psychiatric assess-
ment and treatment are some-
tImes sought for pat1tmts with 
psychosocIal problems. The most 
frequent reasons for referral are 
substance abuse and compliance 
problems. 
Once we have determined that 
a patient needs a liver transplant. 
we evaluate pulmonary. cardiac. 
and renal status in order to gauge 
surgical risk and to prepare for 
the operatIOn. We also conSider 
other risk factors-previous ab-
dominal or portosystemic shunt 
surgery, active infectIOn, and ad-
vanced age. Although risk does 
increase with age. transplanta-
tion can succeed with carefully se-
lected patients aged iO or more.: 4 
The oldest patient In our senes. a 
76-year-old Wom,ln With primary 
blhary CirrhOSIS. IS doing ex-
tremt'iy well more than 18 
months after operation. 
The Jbx.jute cuntraIndicatlOns 
to liver transplantation are mall!;-
nant disea;:;€ out.5lde the liver. a pa-
tient's inabilIty to accept or under-
st.and the procedure. symptomatic 
acqUIred immunodeficiency syn-
drome. and other :P~·"temfC dIseases 
or debllitatmg complicatIOns that 
transplantation cannot reverse. In-
dications for early hepatic trans-
plantation Include major GI bleed-
ing. repea~ bouts of encephalopa-
thy. progressl ve neuropathy. re-
fractory aSCites. a recent preclpi-
tous deterioration in liver function. 
rapid progrE'SE-ion of bone disease. 
and severe wasting. 
The patient's weight. height. 
ABO blood group. and liver vol-
ume as assesi'ed by ultrasound or 
computed tomography leTI tFig-
ure 2\ aid in donor·reclpient 
matchIng. 15 The ultr3sound study 
and CT are also useful means of 
detectIng hepatiC tumors and ex-
cluding extrahepatic extension. 
The results of the evaluation 
are discussed at a weekly confer-
ence attended by the transplant 
surgeons. hepatologists. nurse co-
ordinators. social workers, anes-
thesiologists. radiologists. pathol-
ogists. CrItIcal-care physicians. 
psychiatrists, and sometimes oth-
er specialists. At this meeting. we 
assess the urgency of the patIent's 
need for a transplant. on the 
basis of clinical findings and per-
formance status. a:3 described in 
Table 2. 
While awaiting a donor. pa-
tients who can be managed at 
home return to the care of their 
private physicians. maintaining 
close communIcatIon With the 
citnlc through an aSSIgned nurse 
coordinator Others find local ac· 
commodatlOns and VISIt the clinIC 
once or twice a week. Per:.ons in 
urgent need of transplantatIOn re-
main in the hospital untIl a donor 
becomes a\'allable. to ensure that 
they are In the best pusslble condI-
tIOn at the time of operatIOn. 
INDICATIONS FOR 
TRANSPLANTATION 
Between \farch 1980. when cyclo-
sporine-cortlcosteroid therapy 
KEYPOINTS 
~ A thrombosed. 
portal TeiD is no longer 
an absolute 
contraindication to liTer 
transplantation. Surgical 
repair a1 the time of 
transplantation is 
usually successful_ 
0-. Reformed. 
alcoholics with Laennec's 
cirrhosis can do as well 
after transplantation as 
other cinhotic patients; 
don't exclude them from 
consideration. 
was introduced.. and July 1987. 
666 adults and 334 chtldren un-
derwent liver transplantation at 
programs in Denver and Pitts-
burgh. and at Baylor University 
~1edical Center in Dallas. In 
adults, the most common indica-
tions for transplantation were 
postnecrotic cirrhosis. primary 
biliary cirrhosis. and sclerOSing 
cholangitis: in children. they were 
flGURE 2. Comput~ tomoqrapby 
determines UTer Tolume in a 
transplant r.dpient. as part of 
tile donol'fK1plent ma1ch1nq 
procell. 
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-biliary atresia. inborn errors of 
metabolism, and cirrhosis I Figure 
3\. The one- and five-year actuar-
Ial survival rates for these 1.000 
patients were i1.2'1 and 62.6'1, 
respectlvely.lti Actuarial surVival 
rates by reason for operation ap-
pear In Figure 4 
Postnecrotic cirrhosis. ~1Mst 
patients with cirrhosis. the most 
common Indlcatlon for liver trans-
plantation. have chronic active 
hepatitiS. Some have cryptogenic 
CirrhOSIS. and an Increasing num-
ber have Laennec's cirrhOSIS. 
After transplantation. disease 
often recurs In persons whose ear-
lier serologIC tests were positive 
for hepatitis B surface antigen 
, HBs:\g' Some patients have un-
dergone retransplantation after 
recurrence. but the ri~k of a sec-
ond recurrence IS high. We are 
currently evaluating whether 
Cl-interferon. administered during 
the perloperatlve period to 
HBsAg-posltive patIents and the 
donor livers. w1l1 reduce the re-
currence rate. 
Because of general Ill-health. 
patients With Laennec's CirrhOSIS 
.ire a hlk?h-nsk group. and alco-
holic reclcil\'lSm IS a concern. 
However. transplantatlon should 
be otqert~d to carefully selected pa-
tients who have thiS condition. 
Expenence with our first 41 such 
indiViduals suggests that their 
chances of :,urvl\"al and rehabih-
t.ltlon dre as ~ood as those of 
patients who have nonalcoholic 
cirrhOSIS !ti 
Primary biliary cirrhosis. An 
uncommon disease that most of-
ten d/TeclS mlddle-age-d women. 
primary biliary cirrhosis IS the 
second leading indication for 
tran:,plantatlOn In adults It IS 
charactenzed by Jaundice_ pruri-
tus. hepatomegaly. eas~D fatigabil-
Ity. and bone disease of varying 
severity. Although Its cause is un-
known. it IS belIeved to be an 
autoImmune disease: antlmito-
chondrial antibodies are found In 
over 90r:; of p;itlents. ThyrOiditis. 
lupus erythematosus. scleroder-
ma. renal tubular acidosis. and 
rheumatoid arthritis are likely 
concomitant Illnesses. 
Asymptomatic patients have an 
excellent life expectancy, and 
man~D never de\"elop clinically sig-
nificant organ damage. 17 For 
those who do. medical therapy-
D-pe nici II ami ne. ch lorambuc 11. 
colchicine. corticosteroids. azathi-
opnne. ur cyc\osponne--ha:, heen 
ad\·ocated. but there is little eVI-
dence that these agents are effec-
tive.!" Recent tnals wlth D-pem-
cillamme fadt>d to demonstrate a 
~l!;nlficant bt>nefit. :!,j-21 Once the 
di:"t'ase ha:, progr6=-ed to an ad-
vanced stage. WIth jaundice and 
a:;cltes. liver transplantation is 
the treatment uf cholct.>. Since ad-
\'anced a~eK a debilitated :,tate. 
and disabling bone dlsf.:':.Ise em 
complicate postoper:llIH' reco\"-
E'ry. referral for tran:;plant3tlOn 
should not be delayed. 
Sclerosing cholangitis. ~1ost 
common In young men. sclerOSing 
chulangltls fn·quently OCl'urs In 
assOCiation With uther disorder=-. 
espeCially IBO The InCidence of 
coexisting I.'holangiocarctnoma 
has been reported to be about 
10'( .22 Clin,,:;}l findings :Iu~~cst-
lJVER TRANSPLANTATION 
TABLE 1 
GRADING HEPATIC 
ENCEPHALOPATHY 
Stag. I 
AgitcrtlOn 
Mud cor_fusion 
Tremors 
Stag. D 
Lethargy 
Asteruas 
Stage m 
Delinum 
Somnolence 
SeIZures 
Hyperad:ve reflexes 
Stage rvA 
Coma With respD~rKse :C 
noXlCUS s!L--:1ull 
Stage IVI 
Coma 'With 1:0 respor.se to 
noxIous stlmulJ 
Sow':e AC::;;!eo !:'Orr. Rc~ L Scl'.Jll 
t:i< I~I :. uea:ses ;;r i~e ~ ... er ed 5 
m~Kl1aaelprKjc :e ,-:;)PUlCOIT Co. !982. 
p~9 
tng such a carcinoma mclude an 
exceedingly high bilirubtn. recent 
deterioration in liver function. a 
long history of 5clt!roslng cholan-
gitis. and an elevated level of car-
c.:lnol'mbryonlc antigen. However. 
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C'esMz3'? .pc, iet-rte 
as these findings may be absent. 
everyone with sclero5ing cholan-
gltis should undergo cholangiog-
raphy and brush biopsy of 5uspi-
CIOUS lesions. 
The results of tran5plantatlOn 
In patients with cholanglOcarcin-
oma have been poor: thE'se indi-
viduals should be referred for ra-
diotherapy. We are pre~bDntly con-
sidering preoperative radiothera-
py for patients with small. early 
bile duct cancers. to determine 
whether such treatment reduces 
the incidence of tumor recurrence. 
Sdero5mg cholangitis IS an in-
curable disease. Previous at-
tempts at 5urglcal biliary dIver-
sion and hilar reconstruction usu· 
ally complicate tramplantation. 
Such operatIons should be avoided 
except 10 highly selected patients 
with well-defined. localized extra· 
hepatic lesions. Operation for as-
SOCIated IBD is best deferred until 
three to SIX months after liver 
tran5plantation. 
r~Der tumors. Tran5plantatlon 
should be con51dered for patients 
with advanced hepatiC malignan-
cy and those who have bemgn tu· 
mors that cannot be remo\'ed by 
conventIOnal subtotal resectIOns. 
Types of tumors for whIch pa-
tients have undergone liver trans· 
plantation include hepatocellular 
carcinoma. cholanglOcarclnoma. 
hemangIOendothelioma. neuroen· 
docrlne tumors, and multiple ade-
noma. One patient whose liver 
had been almost entlrely replaced 
by lymphangioma received a 
transplant . .!3 
~1ost patients With tumors are 
excellent candidates for opera· 
~ . ..... 
UVER TRANSPLANTATION 
TABLE 2 
CLASSIFYING PERFORMANCE IN 
PATIENTS WITH LIVER DISEASE 
Per10rmance 
leTel Adult Chilc1 
Worklng or tull-Ilr."le 
student normal grc\.II1h 
2 m~rjally d:sc.tJed. 
capaole 01 sed-care 
At heme mes! of the tIne. 
m:ld to modera1e 
gro'Nth relardatlon 
3 
4 
Homebound ·..nth 
~endan!K 'lr.::.ble 
10 work 
Hcsp!tallZed 
Homebound. renD~es 
profeSSional care. 
unable 10 attend school. 
moderate 10 severe 
qro'Nth retardation 
HOSPllallZed 
5 ~geeds mle~ve care Needs u-.tenslve care 
6 On We support Or. lue support 
5o:..a:ce ,A.:!=;Ie.: :i":~K :I-:t:;:"£ PcIr:l=~K :<:1 7==K.;.S • .!. . .:; e1'J..: Eq'l.:,U®le aK1goc~!CrrK::1 
e~r:!Dl!~:f; oro::.-.. hit:', SpecIO: reler~~K:e :c t~Kb ~ver ~Ksf=DClglfK:>rrx; V88. 2C : ~ 1 : 3/l 
tion. ~lnce portal hypertensIOn 
dnd Its complicatyEFn~ are usually 
not present. Early ~unDfyDal after 
transplantatIOn has been good, 
but long-term surVival has been 
poor because tumors may recur 
fairly soon after tran5plantation. 
PJtlents with a ht'patlc malig-
nancy must be t:'.xamlned thor-
oughly to ddermine that the tu-
mor does not extend beyond the 
confines of the liver. Often. the fi-
nal deciSIOn must be made at sur· 
gery. If a suitablE: donor becomes 
available. the surgeon doe~ an ex-
ploratory operation. proceeding to 
transplantation only If there IS no 
evidence of extrahepatiC tumor 
spread. 
In general. the 5ur .... lval rate af· 
ter transplantation for hepatocel-
lular carcinoma has been poor: 
however. there are exceptions. Pa-
tients who receive transplanta. 
tlon for end-stage liver disease 
and are found to have an inciden-
tal primary hepatiC tumor have 
the .same survl\'sl rate as do oth· 
::A~kCp!p '':''\!v ~o e 13 
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nGUiE 3 
INDICATIONS FOR TRANSPLANTATION 
Other 
SecoDdQJY hepatiC malIgnancy 
BUe duct cancer 
Budd-ClUan syndrome 
Secondary biliary cmhoslS 
F'ulmlncml hepatIc tallure 
f'nm;:uy hepatIc 
maugnancy 
Liver-based inbOrn 
metabollc .nors 
Pnmary 
scler05111g 
cholangttlS 
Adults 
Other 
Neonatal hepatltlS 
Budd-Chlart sync1rome i 
Prunary hepatIC malignancy 
Congemtal hepatiC flbroslS-
Secondary bllla;y cmhoSlS-1 
Fulmmant hepatIC taiJure-
Famlllal 
choleslatic 
syndrome 
LiVer-based inborn 
metabolic enors 
Children 
Between March 1980 and July 1987,666 adults and 
334 children undel'\t.'ent liver traI'.splanlcrtlon crt 
programs in DerNer, Plttsburgrl ane DalJa.s 
Among adults (let!) cirrhosIS was the most commo;_ 
reason lor tral'.spionlatlor. among children (ngh!; 
biliary atresIC 
er~ with the same original di~­
easE:'. and their tumor~ have not 
recurred. 
The fibrolamellar \-ariant of he-
pat0cE'ilular carcinoma tt-nd!' to 
occur in younger patlent5 and IS 
les!:' ag~esRln than other malig-
nant leslons_ Although tumor 
generally recurs. palliatIOn for 
twu or more years can be achieved 
in man~- patIents. Even after re-
currence. the quality of life may 
be good for a prolonged period_ 
which 15 not the case when other 
mailgnancles recur. Liver trans-
plantatIOn for hemangioendothe-
!toma Off£'T5 similarl~- favorablE' 
re~ultRK:!~ 
Conwnt IOnal adJu\'ant chemo· 
therapy and radfltherap~ han 
beoen ui'ed In combinatIon WIth 
liver transplantatIon in an effort 
to improve survIval. but additIOn· 
al folluw·up 15 needed to evaluatE' 
theIr succe55. Furthermore. Im-
munosuppreS51\,E' agE'nts gIven 
durin!, tht· posttransplant p£'riod 
may accelerate the growth of ex· 
trahepatic nests of malIgnant 
cells that were not detected at thE' 
time of transplantation. Improved 
results may have to await the ad· 
\'ent of more selectivE' methods of 
imrnuno5uppres51On 
Biliary atresia. !ybDarl~ ali In-
fants and children who receJ\'t 
transplantation for bilIary atre~ld 
have had a pre\'lOUS operatIon. 
usually a portO€'nterostomy I Ka-
sal procedure I. Prior operatlon In 
thE' TIght upper quadrant. partlcu· 
larl~ in the hepatic hilum. makf'!' 
tran5plantatlon much morE' dIm· 
cult and Increases postoperatIve 
morbidIty Although a well·tlmed 
. -- .-... - .. -=---_qr-.. ---_4 .... clllllll!e"KlDyfi!!_~K-..... _-
.. • ... Wll. ______ .. ____ ............. '. _ ow _ ~K _. 
and properly performed porteen· 
terostomy can be useful. we ad· 
nse restraint rather than liberal 
use of this procedure. especially in 
patients with established cirrho· 
sis. Replacement of the liver is the 
treatment of choice for bihary 
atresia. although the limited 
a·.allabiJity of very small pediat· 
rIC donors continues to be a major 
problem. 
Inborn errors of metabolism. 
~tost patients with inborn errors 
of metabolism are in good health 
otherwise. and few have had pre· 
vious upper·abdominal surgery. 
Thus. they are good candidates for 
transplantation. The one·year 
survival rate is excellent. and no 
deaths have occurred beyond that 
point. 
a·I-AntitrYPsln deficiency and 
Wil.son·s disease are two metabol-
ic diseases that transplantation 
can cure. The former causes a pro-
gresSIVE.> macronodular Cirrhosis 
and obstructive pulmonary dis-
ease: the latter IS associated with 
reduced copper excretion. de-
creased serum ceruloplasmin. and 
excessive deposition of copper in 
the liver and brain. Hereditary 
tyrOSinemia. which causes pro-
gressive cirrhOSIS and Increases 
the risk of hepatocellular cancer. 
is another Indication for opera-
tion. Transplantation has also 
been performed in patients with 
glycogen storage disease. hemo-
chromatosis. and famtlial hyper-
cholesterolemia. 
Budd-Chiari syndrome. Some 
patients given transplants be-
cause of Budd-Chiari syndrome 
requlre extensive thrombectomy 
IJVER TRANSPLANTATION 
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SURVIVAL RATES 
CI:-:hosu eBAAg·n~c:tlve 
J77'\ 
65'\ 
CUlho5U HB$Ag·pCSl!lve 
48% 
140% 
Pruna.'Y bwary CI!-:!:.C5U 
76'\, 
173% 
Sclerosltlg' cholan~lfKs rK:>enlE~nF 
J80," 
Sclerosltlq cholan~tu Wlth btle duct cancer 
01% 
Biliary atrltSla 
Joe% 
105% 
InDom metabol1c enors 
75% 
75' 
Hepc10ma 
149'" 
Fil:>rolamellar hepatoma 
j14'\ 
13O," 
I I I I 
o 40 00 110 100 
PauenlS sumnng ('-) 
lCr( HBsAQ • hepatt!lS B sunace :::r.uoen 
Since 1980. one- and we-year 5Ul'ViVa1 rates after trar.splantatlor. 
have nsen to 712" and 02.0,,". respectively. PaUents W'lth HBsAg-
negatIve ctrrhOSlS. pnmary bWary ctrrhOS15. billary atresla. and 
Inborn errors 0/ metaboUsm have the best proqnOSIS. five-year rates 
lor pa11ents WIth sclel'OSUlQ cholangrt1! are not yel avcnlable. as the 
Jongest-$UMVlng paUents receIved new lIvers lour years ago. There 
have been no we-year SUMVOrs atter transpJantatlOn lor 
nonabrolameUQr hepatoma. 
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LIVtR TRANSPLAN'I'Al'lON 
CURRENT SURGICAL TECHNIQUE 
Operatlon to remove the liver tram a donor IS 
penorrned through a complete midline inclSlon 
trom the suprasternal notch to the pubIS For the 
transplant reclpient. a bilateral subcostal inCISIon 
with a supenor midline T enenslon is almost 
alwcy~ ilSed It should not be ne-:;essary 10 enter the 
chest 
$landard approach to donor. The standard 
techruque ~ Ilrst to diVlde thE' lalci1orm. ler. 
biangular. and gastrohepatic ligaments' and then 
to 11go1e and diVlde the branches of the celJac trunk 
includlng the nght gastnc. gastroduodenal. 
spleruc. and len gastnc artenes The common bile 
duct is divided and the gallbladder flushed out 
The ponal vem is skeleloruzed and the splenic vein 
cannulated The supraceliac aorta is enClTCled for 
later cross-clampmg. Next. the dJstal aorta IS l1gated 
and cannula1ed. The supenor mesentenc artery is 
ligated and diVided. the aorta cross-clamped. and 
ice<e>ld Ringer's solution rapidly in1used through 
the spleruc (portal) vem and the aorta lntusion ot 
preservcruon solubon tollows 
Once the liver has become very cold 11 is removed. 
along with a large cu11 of diaphragm around the 
suprahepatic vena cava and over the bare area 
01 the liver The intrahepatic vena cava is divided 
just above the renal veins The celiac trunk is 
removed. with a cu1! of aorta This technique is 
slightly modlbed when vas".""UIar anomal1es are 
lound l~~ 
II." appt'O('lt:b. Recently. a method that en1ails 
VlI't.lally nc pre!.urunary dISSection of the liver hm 
beer. used 1(;:. The inJenor mesentenc vem and 
dJ.s1al aorta are ligated and cannulated The 
supra celiac aorta IS cross-clamped. and the ice· 
cold i.n1usion through the inJenor mesentenc vem 
and aorta ~K When the lIver IS thoroughly 
cooled. womng in a bloodless beld Wlthout ns.k of 
inadvertent oomprorruse 01 blood flow. the 
surgeon liga1es and dlVides the hilm structures and 
removes the organ as described above 
78 CDigKKdfD·:>~!~ June IQ88 
In both methods. t.!)e tmal dlssection and 
preparation tor anastomosis 01 the vena cava and 
the tailar structures is penormed on the back table 
These methods aUow the sale removal of multlple 
organs (heart or heart·lung. kidney. liver. 
pancreas) in vanous combmations. while 
mamtammg exceUent functJon 
RKlplent operaf1on. Once the abdome:: l! 
entered. the structures 01 the hepatic hilum are 
skele!oruzed. and the hE'patlC arter)' a!"ld c::mmor, 
bile duct are ligated and diVided A pump-<1nven 
venovenous b~ pF~tem WIthout reClplen! 
heparini2ation is used almost routinely in adults and 
children over 30 pounds"; Cannulae lor the bypass 
are placed into the portal. femoral. and axillcny 
vems. With the patIent on bypass. the coronary and 
bian\1ular ligaments are taken down and the vena 
cava is dissected to complete the hepatectomy 
The venovenous bypass allows the surgeon 
suttlclent tune to close the raw sunaces created 
during the hepatectomy It also converts a CrisIS 
enVlTonment dunng the anhepatlc phase o! the 
operatlon into one that is easily controUed. and II 
has reduced intraoperative bleedmg. 
postrevascularu':ltion pulmonary edema and 
cardiac stand.stll!. and postoperatlve renal and 
gastromtestinal dysfunction 
Vascular cutts are fastuoned and the upper and 
lower caval anastomoses performed Alter portal 
anastomOSlS the liver IS repertused. The bypass 
cannulae are removed and hemostasIS secured 
Revasc:ulc:r.zcrtJon oj the liver is completed wilt', the 
artenal anastcrnoslS II t.!)e reclplen: hepone a~e:IFD 15 
inadequa1e an iliac artery grott IS mlerpcsed 
between the donor hepatlc artery and \he 
inlrarenai aorta. through a tunnel created in an 
avascular plane behlnd the pancreas and 
duodenum fl.nally. the biliary tract IS restored. 
USlTlg either a duct-to-duct repcnr over a T·tube stent 
or a choledochoJeJunOS1omy to a Jejunal Roux-en· 
Ylimb 
»>nUl"-·.'olli ... · ......... +scDlli' ................... •...... __ .b ..... _ .... _____ -..-..... _. __ ., .... 
of the portal vein and vena ca .... a. 
and all of them must be main· 
tained on permanent anticoagula· 
tlOn after operation. If antlcoagu· 
lation is interrupted e .... en briefly, 
thrombosis. possibly fatal. may 
recur. 
A LOOK AI THE FUTU"RE 
Future advances in immunology, 
organ procurement and preserva· 
tion. and surgical technique can 
be expected to lead to additional 
improvements in survival and 
quality of life. Progress in organ 
preservation will make more li .... · 
ers available for transplantation 
by extending ischemia time and 
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